Autopsy report · NCT04822259
Evaluate the Performance of JOURNEY II CR and JOURNEY II BCS in TKA Populations
Cause of deathSlow enrollment
“Study design is not reasonable and sponsor decided to terminate the study. No patient enrolled by now”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Na
- Sponsor
- Smith & Nephew, Inc.
- Sponsor type
- Industry
- Conditions
- Arthroplasty; Replacement; Knee
- Interventions
- JOURNEY II BCS Total Knee System; JOURNEY II CR Total Knee System
- Participants
- 0
- Sites
- 5
- Countries
- China, India, Singapore
Trials that died the same way
- Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
“Sponsor decided to terminate the study” - Study of Viziatek ISL™ Refractive Phakic Intra Sulcus Lens for Refraction Adjustment in Blind Volunteers
“Sponsor decision to terminate the study” - A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
“Due to low enrollment, the Sponsor decided to prematurely terminate the study” - A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
“Sponsor decision to early terminate the study” - Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated
“Sponsor decision to terminate study.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.